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ABSTRACT
In recent times, high-throughput screening analy-
ses have broadly defined the RNA cellular targets
of TDP-43, a nuclear factor involved in neurodegen-
eration. A common outcome of all these studies is
that changing the expression levels of this protein
can alter the expression of several hundred RNAs
within cells. What still remains to be clarified is which
changes represent direct cellular targets of TDP-43
or just secondary variations due to the general role
played by this protein in RNA metabolism. Using an
HTS-based splicing junction analysis we identified at
least six bona fide splicing events that are consistent
with being controlled by TDP-43. Validation of the
data, both in neuronal and non-neuronal cell lines
demonstrated that TDP-43 substantially alters the
levels of isoform expression in four genes potentially
important for neuropathology: MADD/IG20, STAG2,
FNIP1 and BRD8. For MADD/IG20 and STAG2, these
changes could also be confirmed at the protein level.
These alterations were also observed in a cellular
model that successfully mimics TDP-43 loss of func-
tion effects following its aggregation. Most impor-
tantly, our study demonstrates that cell cycle alter-
ations induced by TDP-43 knockdown can be recov-
ered by restoring the STAG2, an important compo-
nent of the cohesin complex, normal splicing profile.
INTRODUCTION
Nuclear factor TDP-43 was first described in 2006 as be-
ing the major component of pathological inclusions present
in the brain of patients affected by Amyotrophic Lateral
Sclerosis (ALS) and Frontotemporal Lobar Degeneration
(FTLD-TDP) (1–4). In recent years, large efforts have been
made to identify the cellular targets of this protein. The ob-
vious rationale for this search was to identify genes that
are directly affected by TDP-43 and that could therefore
represent primary targets for corrective therapies or for
biomarker analysis to monitor disease onset/progression
(5–7).
In theory, finding TDP-43 cellular targets at the mRNA
level should be a rather straightforward task. Indeed, like
most hnRNPs, one of the major distinguishing features of
TDP-43 is its ability to bind RNA in a very specific man-
ner through the presence of two RRM motifs within its
sequence (8,9) and following the earliest description of its
RNA binding preferences, it has been long known that
TDP-43 preferentially binds UG-repeats and UG-rich se-
quences (8). These observations were subsequently con-
firmed by CLIP analyses (10,11) and a high resolution
nuclear magnetic resonance structure of TDP-43 binding
to one of these sequences has been recently solved (9). It
should also be considered, however, that the presence of a
potential binding site does not always mean it will play a
fundamental functional role in a particular process (12). In
addition, the functional consequences of TDP-43 binding
to a particular element may not be predicted in a straight-
forwardmanner, as has been recently exemplified in the case
of the human SORT1 gene where TDP-43 plays a different
role in regulating the human exon 17b inclusion as opposed
to the one observed in exon 17b gene of the mouse Sort1
gene (13).
In recent years, the search for functional RNA binding
targets has been greatly aided by the development of sev-
eral high-throughput screening approaches (HTS) that al-
low analysis of changes in RNA processing events on a
global scale, without any subjective bias aside from individ-
ual technical or sample collection limitations (14,15). As ex-
pected, many bioinformatics-based/HTS techniques have
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already been used to explore TDP-43 targets in several ex-
perimental systems. At present, these range from looking
at gene expression changes following straight knock-out or
mutant expression of this protein in a variety of cultures in-
cluding primary and neuronal cell lines (10–12,16–23), in
mouse/fly in vivo models (24–28), iPSC cell lines derived
fromALSpatients carryingTDP-43 disease-associatedmis-
sense mutations (29) and even in myofibers collected from
patients affected by sporadic Inclusion Body Myositis (30).
All these approaches have yielded a huge number of
genes whose expression/splicing levels become altered fol-
lowing changes in TDP-43 expression/localization. This re-
sult is not surprising if we consider the high number of
molecular pathways in which TDP-43 seems to be involved,
that include mRNA/lncRNA/miRNA processing, mRNA
transport/stability and mRNA translation (3). However,
this abundance of targets also suggests that all of these
changes can not be ascribed to a direct consequence of just
TDP-43 action, as recently reviewed by us (6). The reason
being that most hnRNPs regulate mRNA splicing processes
in a highly cooperative manner (31–33) and it is possible
thatmany of the TDP-43 functional roles can also be depen-
dent on the presence of specific partners. Indeed, TDP-43 is
certainly no exception to this situation at least with regards
to its role in splicing regulation (34).
To date, there are still very few genes whose splicing
is known to be directly affected by TDP-43 levels at en-
dogenous level (5). Among these, the best characterized
are: human CFTR exon 9 (35), SKAR/POLDIP3 exon 2
(36,37), intron 7 in the 3′ UTR of TDP-43 mRNA (38)
and Sort1 exon 17b (13). In addition, substantial changes
in the endogenous protein production in neuronal cell
lines following TDP-43 depletion were shown only for
SKAR/POLDIP3 and the TDP-43 protein itself (36–38).
From the point of view of understanding TDP-43 pathol-
ogy, therefore, this could represent a crucial aspect of future
therapeutic approaches. In fact, several lines of evidence
from animal and cellular models are supporting the hypoth-
esis that loss of normal TDP-43 function in the nucleus as
a result of its sequestration in the insoluble aggregates, may
represent the key factor in TDP-43 proteinopathies (39).
In order to increase our knowledge of the consequences
of TDP-43 depletion in the cell we have now performed a
series of overlapping HTS taking advantage of a series of
very similar HEK293 cell lines that can be induced to ex-
press a variety of TDP-43 mutants (40). Due to the simi-
lar background between these lines, this approach has been
particularly useful in identifying several novel genes where
TDP-43 can play a direct role in regulating protein isoform
production.
MATERIALS AND METHODS
Cell culture, RNA interference and RNA purification for mi-
croarray analysis
Flp-In HEK293 (Invitrogen) with inducible siRNA resis-
tant FLAG-tagged wild-type TDP-43, F4L mutant and
TDP43–12XQ/N aggregation effector have been described
in detail before (40,41). Cells were cultured in DMEM-
Glutamax-I (GIBCO) supplemented with 10% fetal bovine
serum (EuroClone). Induction of tagged TDP-43 expres-
sion was achieved with 1 g/ml tetracycline (Sigma).
Depletion of endogenous TDP-43 was performed by
RNA interference using HiPerFect Transfection Reagent
(Qiagen) and siRNA specific for TDP-43 (Dharmacon; tar-
get sequence 5′-aagcaaagccaagaugagccu-3′). Shortly before
transfection 5 × 105 cells were seeded in 6-well plates in 1.4
ml of culture medium containing serum and antibiotics. A
total of 3 l of 40 M siRNA TDP-43 was diluted in 91
l of Opti-MEM (Life Technologies) and 6 l of HiPer-
Fect Transfection Reagent (Qiagen) was added to the di-
luted siRNA.Following 10min of incubation the complexes
were added drop-wise onto the cells. After 24 h the same
procedure was performed with the exception that the cells
were detached from the 6-well plates and re-seeded shortly
before transfection. Three siRNA transfections were per-
formed for each experiment. The siRNA against the fire-
fly luciferase gene was used as a control (Dharmacon Non-
Targeting siRNA #2).
SiRNA mediated interference of endogenous STAG2
exon 30b-containing-isoform was performed in HeLa
cells using two sets of siRNA: STAG2 siRNA A1
Fw: 5′-uagcucaaagacaacaaga[dT][dT]-3′ and Rv: 5′-
ucuuguugucuuugagcua[dT][dT]-3′; STAG2 siRNA A2
Fw: 5′-gcgaacuaaucuucagcau[dT][dT]-3′ and Rv: 5′-
augcugaagauuaguucgc[dT][dT]-3′ (Sigma-Aldrich). Each
siRNA was used at a final concentration of 80 nM using
Oligofectamine Transfection reagent (Life Technologies)
according to manufacturer’s instructions. The siRNA
transfection procedure was performed twice in two consec-
utive days. On the third day cells were collected. Similarly,
siRNA-mediated depletion of TDP-43 in HeLa cells was
carried out using a final concentration of 80 nM of the pre-
viously described siRNA and Oligofectamine Transfection
reagent (Life Technologies) according to manufacturer’s
instructions.
Total RNA from individual samples was purified using
TRIzol reagent (Invitrogen) according to manufacturer’s
instructions. Specifically for the microarray analyses, total
RNA extracted from four groups of HEK293 cells: control
cells (siRNALuciferase), cells depleted of TDP-43, cells ex-
pressing inducible siRNA resistant FLAG-tagged wild-type
TDP-43 or F4L mutant, underwent RNA quality control
and microarray analysis at GenoSplice (France).
Microarray and data analysis
Affymetrix HJAY were normalized using ‘Probe scaling’
method and background corrected with ProbeEffect from
GeneBase (PMID: 18984598). Gene expression index was
computed from probes that were selected using ProbeSelect
from GeneBase (PMID: 18984598). The gene expression
signal was computed using these probes. Genes were con-
sidered expressed if mean intensity ≥500. Genes were con-
sidered as regulated if (i) they were expressed in at least one
condition (e.g. siTDP43 and/or siCTRL); (ii) fold-change
was greater or equal than ≥2 and; (iii) unpaired t-test P-
value between gene intensities was ≤0.05.
For each probe, a splicing-index was computed. Un-
paired t-tests were performed to test the difference in probe
expression between the two samples as described previously
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(PMID: 24623796, 4358235, 23393189). Probe P-values in
each probeset were then summarized using Fisher’smethod.
Using annotation files, splicing patterns (cassette exons,
5′/3′ alternative splice sites and mutually exclusive exons)
were tested for differences between isoforms, selecting the
ones with a minimum number of regulated probeset (with
a P-value ≤ 0.01) in each competing isoform. For example,
for cassette exon, the exclusion junction and at least one of
the three inclusion probesets (one exon probeset and two in-
clusion junction probesets) have to be significant and have
to show an opposite regulation for the splicing-index.
These data are publicly available from the GEO NCBI
database. The ID for our datasets is the following:
GSE67195.
Minigene constructs
For the MADD minigene, exon 31 together with
278 and 261 bp of 5′ and 3′ flanking intronic se-
quences were amplified using forward primer 5′-
ccatatggaggccagcagcagggccttcgg-3′ and reverse primer
5′-ccatatggttcactgagctgcttcaggacc-3′. Both primers con-
tained NdeI restriction sites at the 5′ ends that were
used to clone the 609 bp fragment into the pTB reporter
minigene, which is a modified version of the -globin-
fibronectin-EDB minigene. For STAG2, a three-exon
minigene construct was prepared using the following
primers: one set 5′-cggggtaccctgaagaaagtagtagtagtgacag-3′
forward and 5′-ataagaatgcggccgccaatggggagccacaga-
3′ reverse, was used to amplify the first fragment of
898 bp (exon 30, intron 30, exon 30b and 508 bp of
downstream intronic sequence) whereas the second set,
5′-ataagaatgcggccgcctctgtttgccatggtagac-3′ forward and
5′-atatatgggccccaaatctatatccatggtgtcaaaatcc-3′ reverse were
used to amplify the second fragment of 737 bp (610 bp
of upstream intronic sequence of exon 31 and exon 31
itself). The two fragments were sequentially cloned into
the pcDNA3 vector. All constructs were confirmed by
standard Sanger sequencing prior to transfection.
Mutagenesis in both MADD and STAG2 minigenes
was performed using the Quik-change R© Site-Directed
mutagenesis kit according to the manufacturer’s guide-
lines. Specifically for the MADD intronic sequence
(5′-gtgtgctgtgt-3′) the primers: MADD MUT Fw (5′-
gggtggggctgtagctgggagaACAtAcCgCgaggggcaggggtgg
agcctgtgggc-3′) and Rv (5′-gcccacaggctccacccctgcccctc
GcGgTaTGTtctcccagctacagccccaccc-3′), mutated nu-
cleotides in capital letters, were used in the mutagenesis
polymerase chain reaction (PCR). Mutants were then
confirmed by sequencing. For STAG2, the two sets of
primers used for deletions of fragments 3 and 5 consisted
of STAG2delta3 Fw 5′-ctattgtattagcttcatcattttccatt-3′ and
Rv 5′-aatggaaaatgatgaagctaatacaatag-3′ and STAG2delta5
Fw 5′-tgagtgagtgcgcgcatgcctggtacaccatcattttccattatacttga
atatag-3′ and Rv 5′-ctatattcaaagtataatggaaaatgatggtgta
ccaggcatgcgcgcactcactca-3′. DpnI digestion at 37◦C was
performed for all PCR products prior to transformation in
DH5 Escherichia coli cells.
Approximately 3g of eachminigene expression plasmid
was transfected into the cells using amodified calciumphos-
phate (CaPO4) precipitation method. This was performed
after 72 h of RNA interference and cells were incubated at
37◦C with 5% CO2 for 24 h.
Standard RT-PCR analysis
Total RNA from individual samples was purified us-
ing TRIzol reagent (Invitrogen) according to manu-
facturer’s instructions. The cDNA synthesis was per-
formed using 1 g of each RNA sample and Moloney
murine leukemia virus reverse transcriptase (Invitrogen)
and random hexameric primers. PCR analysis was per-
formed using the following primers: BIM/Bcl-2 Fw 5′-t
ctgagtgtgaccgagaagg-3′; BIM/Bcl-2 Rv 5′-tcttgggcgatccat
atctc-3′; SKAR/POLDIP3 Fw 5′-gcttaatgccagaccgggagttg
-3′; SKAR/POLDIP3 Rv 5′-tcatcttcatccaggtcatataaatt-3′;
STAG2 Fw 5′-gtatgtttacttggaaaagttcatg-3′; STAG2 Rv 5′-t
gattcatccataattgaagctgga-3′; MADD Fw 5′-gacctgaattggg
tggcgagttccct-3′;MADDRv 5′-cattggtgtcttgtacttgtggctc-3′;
FNIP1 Fw 5′-gctacaagatagtcttgaattcatc-3′; FNIP1 Rv 5′-c
agaccgtgctatgccactgtctct-3′; BRD8 Fw 5′caattcttggccacg
cagttgatta-3′; BRD8 Rv 5′-ctcagagagaaagtggaggaggttc-3′.
The primers used in amplification of all the other genes
tested in this study and listed in Supplementary Figure S4
are available upon request.
In all experiments exon inclusion/exclusion was quanti-
fied using Image J according to the methodology described
in (42).
Recombinant GST-TDP-43 purification, western blots and
antibodies
The production and purification of GST-TDP43 in a bac-
terial expression system has already been described (35).
Western blots were performed according to standard pro-
tocols using the following antibodies: home-made rabbit
polyclonal antibody for TDP-43 previously described by us
(35), home-made mouse polyclonal antibody for tubulin,
rabbit polyclonal antibody for STAG2 (Cell Signaling Tech-
nology) and polyclonal rabbit antibody for MADD (Santa
Cruz).
Electrophoretic-mobility shift assays (EMSA)
For MADD exon 31 electrophoretic-mobility shift assays
(EMSA) analysis, 278 bp of exon 31 immediate upstream
intronic sequence were selected and divided into three sep-
arate fragments by PCR amplification with primers con-
taining a T7 promoter sequence on the forward primer of
each pair that would allow T7 in vitro transcription. The re-
sultant RNA was used in the band shift analysis. Primers
used in the amplification of eachMADD fragment were as
follows:MADDIn30Fg1Fw: 5′-TACGTAATACGACTCA
CTATAGGaggccagcagcagggccttcgggttg-3′ (capital letters
indicate T7 promoter sequence) andMADDIn30 Fg1Rv: 5′-
accttccgctcctggcc -3′,MADDIn30Fg2Fw:
5′-TACGTAATACGACTCACTATAGGtacatgc
cctttctgctatcttcgct-3′ and MADDIn30Fg2Rv: 5′-
aagaaagtctatttcc-3, MADDIn30Fg3 Fw: 5′-TACGTA
ATACGACTCACTATAGGtgtgtgggtggggctgtagc-3′ and
MADDIn30Fg3Rv: 5′-ggtaaggcccacag-3′. PCR products
obtained were then gel purified and used as templates
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for in vitro T7 (Stratagene) RNA transcription. Integrity
of all transcribed RNA fragments was confirmed by
electrophoresis on a 1.5% agarose formaldehyde gel
(Supplementary Figure S7A). The produced RNA was
used as competitor to the positive (TDP-binding) control
RNA oligo (UG6), which was synthesized by Sigma and
radio-labelled using  -32P adenosine triphosphate (ATP)
(PerkinElmer) and T4 polynucleotide kinase (New England
Biolabs). Briefly, 5 l of RNA oligo (100 ng/l), 1X T4
polynucleotide kinase buffer, 1 l of T4 polynucleotide
kinase (10 U/l, New England BioLabs) and 1 l of  -32P
ATP (100 Ci/l) were incubated for 1 h at 37◦C. The la-
belled oligo was then precipitated in three volumes ethanol
and 3MNaAc pH 5.2 for an 1 h on dry ice and subsequently
washed with 70% ethanol. Following centrifugation, the
air-dried pellet was resuspended in 50 l dH2O and 1 l
used in the binding reaction. Protein binding reactions with
the labelled oligo with or without the competitors were
performed in 1X binding buffer (10 mM NaCl2, 10 mM
Tris pH 8.0, 2 mM MgCl2, 5% Glycerol and 1 mM DTT)
containing RNase inhibitor 1U/l (Life Technologies) for
10–20 min at room temperature prior to electrophoresis on
a 6% Polyacrylamide gel at 100 Volts for 1.5 h in 0.5X Tris
borate/ethylenediaminetetraacetic acid buffer at 4◦C. The
gel was then dried on 3MM Whatman paper and exposed
on a CycloneTM Phosphor screen (Packard).
Similarly, for the STAG2 3-exon minigene EMSA anal-
ysis exon 30b together with 1041 bp of the down-
stream intronic region was divided into five separate frag-
ments by PCR amplification using primers containing
a T7 promoter sequence. Primers used in the amplifi-
cation of each fragment were as follows; STAG2 Frag-
ment 1: Fw 5′-TACGTAATACGACTCACTATAGGcac
gcaggtaacatggatgtta-3′ (capital letters indicate T7 pro-
moter sequence) and Rv 5′-atggcatgctga-3′, Fragment
2: Fw 5′- TACGTAATACGACTCACTATAGGgtaagtg
agagtgccttatt-3′ and Rv 5′-aagctaatacaata-3′, Fragment
3: Fw 5′-TACGTAATACGACTCACTATAGGtctaactgg
ttttcttccctcaa-3′ and Rv 5′-gtgtaccaggcatg-3′, Fragment
4: Fw 5′-TACGTAATACGACTCACTATAGGctgtcacgt
agtaggcattgtgtgagtgagtgcgcgca-3′ andRv 5′-gtgtaccaggcatg
cgcgcact-3′, Fragment 5: Fw 5′-TACGTAATACGACTCA
CTATAGGattaggtactgaatgaatga-3′ and Rv 5′-gaattaaagg
tcag-3′. Resultant PCR products were then gel purified and
used as templates for in vitro T7 (Stratagene) RNA tran-
scription. Integrity of all transcribed RNA fragments was
confirmed by electrophoresis on a 1.5% agarose formalde-
hyde gel (Supplementary Figure S7B). Competition binding
analyses were performed against a known positive binder
(UG6) of TDP-43, described above.
Quantitative real time PCR analysis
RNA extraction and cDNA synthesis was performed
as previously described. In addition, in order to de-
tect genomic DNA contamination, parallel cDNA syn-
thesis reactions for each RNA sample were performed
in the absence of reverse transcriptase. The quantifica-
tion of gene expression levels was performed by real-
time PCR using SYBR green technology. Specific primers
for STAG2, MADD, FNIP, BRD8 and GAPDH genes
were designed using Beacon designer software (Bio-Rad)
and are as follows: STAG2 Fw 5′-aaaatcaaaaccatctacagg-
3′, STAG2 Rv 5′-tactactactttcttcagtgag-3′, MADD Fw
5′-tctcaagcgcctggtg-3′, MADD Rv 5′-ctctcgaaggtcatgcag-
3′, FNIP1 Fw 5′-cattcctctcagagtgtgg-3′, FNIP1 Rv 5′-
ccatgtcttgtcgtttgc-3′, BRD8 Fw 5′-gcagcctgttacagatgac-3′,
BRD8 Rv 5′-aatagttgacaaatccataggc-3′. The housekeeping
gene GAPDH was used to normalize the results. All ampli-
fications were performed on a CFX96 real-time PCR detec-
tion system (Bio-Rad). The relative expression levels were
calculated according to Livak method (43), using the equa-
tion CT = CT(target) – CT(normalizer) for Ct normalization;
and the difference between CT test (anti-TDP-43 siRNA-
treated cells) and CT calibrator (anti-luciferase siRNA-
treated cells) to calculate the expression ratio and compare
the expression levels of genes of interest. The data shown are
the mean fold induction ± SD from three independent ex-
periments. Statistical significance was calculated using stu-
dent’s t-test (indicated as *** for P ≤ 0.001; as ** for P ≤
0.01 and as * for P ≤ 0.05. NS stands for not statistically
significant).
Fluorescence-activated cell sorting analysis (FACS)
Cell cycle profiles (DNA content) of differentially treated
HeLa cells were performed by DNA staining with propid-
ium iodide (Sigma-Aldrich) and flow cytometry on a FAC-
SCalibur apparatus (Becton Dickinson). The cell distribu-
tions of cell cycle profile were determined by a Modfit LT
3.0 and FlowJo software.
RESULTS
TDP-43 expressing cell lines and splice sensitive microarray
analysis
In order to investigate TDP-43 effects on alternative splic-
ing profiles we took advantage of two previously described
HEK293 cell lines (40) that express, upon tetracycline
induction, a siRNA-resistant wild-type TDP-43 (FLAG-
TDP43-WT) or a siRNA-resistant mutant unable to bind
RNA (FLAG-TDP43 F4L). The experimental design of
this experiment consisted in obtaining four separate mi-
croarray datasets. The first was a control sample derived
fromHEK293 cells treated with a control luciferase siRNA
(Figure 1A, Cont.). The second sample was obtained from
RNAi-TDP-43 depleted HEK293 cells (Figure 1A, Sam-
ple A). The third sample was from cells where RNAi-TDP-
43 depletion was rescued by inducing the production of a
siRNA-resistant TDP-43 WT protein (Figure 1A, Sample
B). Finally, the fourth sample was obtained from TDP-43
depleted cells producing a siRNA-resistant TDP-43 mutant
that could not bind RNA (F4L, Figure 1A, Sample C).
In order to provide a uniform background for comparison
with Sample B and C, tetracycline was also added to the
control and RNAi-TDP-43 depleted cells HEK293 (Figure
1A, Cont and Sample A).
After total RNA extraction of triplicate independent
batches from each set of samples the isolated mRNAs
were hybridized using Affymetrix Hjay (Junction Arrays)
at Genosplice (France) (raw data are available in the GEO
NCBI database with the following ID: GSE67195). These
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Figure 1. TDP-43 expressing cell lines and splice sensitive microarray analysis. (A) The first panel on the left shows the control HEK293 Flp-In T-rex
cell line, the central panel shows the HEK293 Flp-In T-rex cell line that can inducibly express a siRNA-resistant wild-type TDP-43 (FLAG-TDP43-WT)
and the right panel shows the HEK293 Flp-In T-rex cell line that can inducibly express a siRNA-resistant mutant form of TDP-43 unable to bind RNA
(FLAG-TDP43 F4L). Each group of cells was treated either with control Luciferase siRNA or TDP-43 siRNA. All cells were also treated with Tet in order
to provide identical conditions for analysis. Expression ofWT TDP-43 and the F4Lmutant and endogenous TDP-43 silencing were determined by western
blot analysis using a polyclonal antibody against this protein. An anti-tubulin antibody was used as protein loading control. Samples used for microarray
analysis are indicated as Control, Sample A, Sample B and Sample C. (B) Venn diagram showing which type of splicing events were further analysed. (C)
KEGG analysis showing the cellular pathways in which the selected genes are involved.
arrays provide exon and exon-junction analyses and can as-
sess a change in exon inclusion in all known human tran-
scripts based on combined junction and exon evidence. In
particular, they are able to detect three types of splicing
events: differential cassette exon splicing,mutually exclusive
splicing and differential use of 5′/3′ splice sites.
The differences in splice site usage detected in Samples A,
B and C (Figure 1B) were then compared with each other to
find events consistent with a direct effect of TDP-43. This
was considered to occur if they satisfied all three of the fol-
lowing criteria: (i) events must be altered following deple-
tion of TDP-43 (Sample A), (ii) events must be rescued by
the induction of the flagged si-resistant TDP-43 WT (Sam-
ple B), (iii) events cannot be rescued following induction of
the flagged si-resistant TDP-43 F4Lmutant (Sample C). As
shown in the Venn diagram of Figure 1B, the number of
splicing events that satisfied all these three requirements was
145.
The Kyoto Encyclopaedia of Genes and Genomes
(KEGG) database (44) was used for retrieving pathway in-
formation of this splicing event list. The combination of
pathway data and gene ontology analysis of differentially
spliced genes was visualized by a pie chart using colour
codes indicating the distribution of the implicated biolog-
ical processes. Interestingly, this analysis showed that splic-
ing variations were mostly enriched in genes involved in
Alternative Splicing/RNA binding and Phosphoproteins
(Figure 1C). In addition, many genes present in this list
were also related toUbl conjugation pathway and apoptotic
pathways that have previously been associated with TDP-
43 (see Discussion). This narrowed-down number of genes
represented a substantial enrichment compared to the more
than 900 splicing events that were detected to change fol-
lowing antisense-mediated depletion of TDP-43 in mouse
brains (11) or the list of several hundred geneswhose expres-
sion was altered following TDP-43 depletion in various cell
lines (16,17). In relation to these previously reported results,
very little overlap was observed between the genes detected
in our screening and the ones reported in these studies (Sup-
plementary Figure S1). As alreadymentioned, however, this
is not particularly surprising andmaywell reflect differences
at the technical/methodological level as well as the possibil-
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ity that TDP-43 functions may vary considerably from cell
to cell. In addition, it should be noted that changes in ratio
of splicing isoforms within the same gene do not necessarily
imply changes in gene expression (see below).
All the 145 genes were divided into three different Venn
diagrams accordingly to the alternative splicing event anal-
ysed and the full list of names of the genes is reported in each
of the closed boxes in Supplementary Figure S2. Firstly,
from this list it can be noted that among the positive hits
both BIM and SKAR/POLDIP3 were present, two genes
that were previously reported and shown to change follow-
ing TDP-43 depletion by several laboratories (10,36). In-
deed, the splicing profile of BIM confirmed that removing
TDP-43 from cells induced a shift towards the increased ex-
pression of the pro-apoptotic BIMS isoform with respect to
the anti-apoptotic isoforms BIML/BIMEL (Supplementary
Figure S3A, compare lanes 1 and 2). Most importantly, this
shift in splicing isoforms could be reverted in the cells that
expressed a wild-type si-resistant TDP-43 (lane 3) and no
rescue could be observed in the cell line expressing the F4L
mutant (lane 4). In keeping with this pattern, the same type
of influence on splicing for SKAR/POLDIP3, could also be
observed, where inclusion of exon 3 was abolished follow-
ing endogenous TDP-43 depletion (Supplementary Figure
S3B, lane 2), rescued by the expression of the si-resistant
FLAG-TDP43 WT (lane 3) and not rescued by the FLAG-
TDP43 F4L mutant (lane 4).
The list of 145 genes was also analysed according to three
types of splicing events: (i) differential cassette exon splic-
ing, (ii) mutually exclusive exon splicing events, and (iii) dif-
ferential usage of 5′/3′ splice sites (Figure 2A–D). As shown
in these figures, the splicing events mediated by TDP-43
highlight an increased number of cassette exons included
when TDP-43 is silenced or inactivated, suggesting that in a
majority of cassette exons TDP-43 acts as a negative regula-
tor of splicing (Figure 2A). With regards to mutually exclu-
sive exons, it is observed that absence/inactivation of TDP-
43 leads to the preferential inclusion of exon 2 in compari-
son to exon 1 (Figure 2B and C). Finally, although numbers
were very low, an increased number of exons short form gen-
erated by alternative 5′ and 3′ss usage compared to exons
long form was also observed (Figure 2D).
Identifying new genes whose splicing and protein expression
profile was affected by TDP-43 depletion
In order to identify new candidates whose splicing pro-
file was clearly altered in the same manner as BIM and
SKAR/POLDIP3, gene candidates listed in Supplemen-
tary Figure S2 that presented more than a two-fold change
in their splicing profile were tested for subsequent valida-
tion and are reported in Supplementary Figure S4A. It
should be noted that in this screening we looked for genes
in which splicing alteration could be readily detected us-
ing standard RT-PCR approaches and not using more sen-
sitive techniques such as RT-qPCR. The reasoning behind
this choice was to facilitate a search for genes whose splic-
ing profile would very likely result in a robust change in
protein isoforms, as previously described, for example, for
SKAR/POLDIP3. As such, for genes in which no clear al-
teration in the total ratio of splicing profile could be de-
tected (Supplementary Figure S4B), no further analysis was
pursued. Thus, the four best candidates to be further char-
acterized at the protein level were the following: STAG2
(Figure 3A), MADD (Figure 3B), FNIP1 (Figure 3C) and
BRD8 (Figure 3D). As shown in Figure 3, in all these genes
each relevant exon behaved as would be expected of an
exon dependent on TDP-43 for definition. Briefly, exon in-
clusion levels where affected when TDP-43 was removed,
were restored by the presence of wild-type siRNA-resistant
TDP-43, but could not be restored by the adding-back of a
siRNA-resistant TDP-43 lacking the ability to bind RNA.
At the protein level, the consequence of the splicing events
in STAG2, FNIP1 and BRD8 genes was predicted to be the
insertion/removal of a particular set of amino acids in the
final protein sequence (shown in Supplementary Figure S5).
In the case of MADD/IG20, on the other hand, exclusion
of the affected exon was predicted to introduce a premature
stop codon possibly leading to degradation of the transcript
by Nonsense Mediated Decay (NMD) (see below).
Validating the genes affected by TDP-43 depletion at the pro-
tein expression level
To test whether these changes in splicing profile were re-
flected in the level of the protein isoforms produced by
their differentially processed mRNAs, western blots were
performed using antibodies directed against STAG2 and
MADD (Figure 3E). These showed that the protein iso-
forms were changing accordingly to the observed changes
in the mRNA isoforms.
In particular, for STAG2 the protein isoform that in-
cludes exon 30b is normally barely visible in HEK293 con-
trol cells (Figure 3E, lane 1). However, it becomes read-
ily detectable following TDP-43 depletion (Figure 3E, lane
2), is repressed again by the production of the wild-type
siRNA-resistant TDP-43 (Figure 3E, lane 3), but is not re-
pressed when the F4L mutant is expressed in the absence of
endogenous TDP-43 (Figure 3E, lane 4). Furthermore, at
themRNAexpression level the overall expression ofSTAG2
was not affected by TDP-43 removal (Supplementary Fig-
ure S6), suggesting that changes in isoform expression do
not significantly alter the total amount of STAG2 proteins
in cells (in accordance with the western blots).
In the case of MADD, exclusion of exon 31 sequence
gives rise to a truncated isoform due to the introduction
of a stop codon within the mRNA sequence that will trun-
cate any resultingMADDprotein isoform before its normal
stop codon. In the control HEK293 cells, two isoforms of
this protein are expressed in almost equal proportions (Fig-
ure 3E, lane 1). Based on the commercial antibody speci-
ficity, the upper band should correspond to the full length
MADD protein that includes exon 31. Following TDP-43
depletion, the expression of the upper band is decreased
(Figure 3E, lane 2). This decrease is reversed following over-
expression of TDP-43WT (Figure 3E, lane 3) but not TDP-
43 F4L mutant (Figure 3E, lane 4). At the overall gene
expression level, furthermore, the results of an RT-qPCR
(Supplementary Figure S6) showed that exon 31 skipping
is associated with a significant reduction in the expression
of the MADD gene (primers were chosen to amplify all
isoforms). This observation is consistent with western blot
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Figure 2. Analysis of the splicing events mediated by TDP-43. (A) Bar graphs show the number of exons included (Up) and excluded (Down) of the cassette
exons analyzed. (B and C) Bar graphs show the number of exons included (Up) or excluded (Down) of the nine mutually exclusive exons analysed (exon
1 in B and exon 2 in C). (D) Bar graphs show the number of exons included (Up) and excluded (Down) of the analysed alternative 5′/3′ splice sites (exon
short form, left graph, and exon long form, right graph).
results. However, no complete recovery in expression lev-
els could be detected when the wild-type siRNA-resistant
TDP-43 was added back (Figure 3E, lane 3). At the mo-
ment, we have no explanation for this but it may well be that
protein recovery levels are lagging behind mRNA recovery
because of its very high molecular weight.
Finally, western blot analysis could not unfortunately be
performed for the BRD8 and FNIP1 genes as antibody
preparations against these proteins failed to specifically de-
tect them in a satisfactory manner (data not shown). How-
ever, RT-qPCR of their overall expression levels detected a
significant increase in the total amount of RNA, suggesting
that, upon TDP-43 depletion, also this property might be
affected in addition to splicing isoforms ratio (Supplemen-
tary Figure S6).
Mapping the interaction between TDP-43 and MADD se-
quences
To better characterize the interaction between TDP-43 and
theMADD gene it was of interest to investigate the mecha-
nism through which TDP-43 was promoting the inclusion
of exon 31. We used an EMSA approach to investigate
which region was the TDP-43 target. Firstly, we analysed
the immediate upstream intronic sequence ofMADD exon
31 since it contained a tg-gt stretch (Figure 4A, underlined)
and pyrimidine-rich sequences, to which TDP-43 has been
reported to bind in some cases (21). The intron was divided
into three fragments (listed in Figure 4A) whichwere in vitro
transcribed and used in an in vitro binding experiment to
determine their specificity in competitively binding to re-
combinant GST-TDP-43 WT in the presence of a (UG)6-
repeated sequence oligo (8). The integrity of the in vitro
transcribed fragments was verified in an agarose formalde-
hyde gel (shown in Supplementary Figure S7A). From this
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Figure 3. Effect of TDP-43 on the alternative splicing of selected genes. Differentially treated HEK293 stable cell lines were used to validate each candidate
gene: control siRNA Luciferase transfected cells (lane 1, si cont.), depleted of TDP-43 (lane 2, siTDP43), depleted of endogenous TDP-43 but expressing
a siRNA resistant transgenic TDP-43 (lane 3, siTDP43 + TDP43wt), depleted of endogenous TDP-43 and expressing a mutant form of a siRNA resistant
protein unable to bind RNA (lane 4, siTDP43 + F4L). (A) Standard RT-PCR of STAG2 transcripts. The diagrams on the right are a schematic represen-
tation of the amplicons. The grey box represents the alternative exon 30b. (B) Standard RT-PCR of MADD transcripts. The diagrams on the right are a
schematic representation of the amplicons. The grey box represents the alternative exon 31. (C) Standard RT-PCR of FNIP1 transcripts. The diagrams on
the right are a schematic representation of the amplicons. The grey box represents the alternative exon 7. (D) Standard RT-PCR of BRD8 transcripts. The
diagrams on the right are a schematic representation of the amplicons. The grey box represents the alternative exon 20. (E) Endogenous STAG2 andMADD
protein expression levels following treatment with siTDP-43 (lane 2), rescue in the cell line expressing an si-resistant TDP-43 (lane 3, siTDP43+TDP43wt),
and following expression of the RNA-binding impaired mutant F4L (lane 4, siTDP43 + F4L). Anti-tubulin was used for protein loading control.
experiment, an increase in unbound labelled (UG)6 was
observed when fragment 3 was used (Figure 4B, arrow).
Interestingly, fragment 3 contained the tg-gt repeated se-
quence mentioned above (Figure 4A, underlined). To ver-
ify whether this sequence was indeed responsible for the
TDP-43 binding, we used a small RNA oligo carrying this
sequence to compete with (UG)6-repeated oligonucleotide.
As expected, an increase in unbound labelled (UG)6 was
observed when we used the small intronic sequence (Fig-
ure 4B, right panel). To functionally test this interaction we
created a hybrid minigene containing the whole sequence
of MADD exon 31 together with 278 and 261 bp of up-
stream and downstream flanking intronic regions, respec-
tively (Figure 4A). Analysis of the mRNA produced from
the minigene following transfection confirmed that knock-
down of TDP-43 resulted in an approximate four-fold de-
crease in efficiency of exon 31 recognition (Figure 4C). Sub-
sequently, to functionally confirm the significance of TDP-
43 binding to the intron flanking MADD exon 31, we mu-
tated the tg-gt rich sequence upstream of the exon in order
to destroy the TDP-43 binding site (mutant pTB/MADD
GT Mut, which nucleotide changes are shown in Figure
4A, bottom panel). As shown in Figure 4D, this mutation
resulted in an increased skipping of this exon (left panel).
Importantly, when we transfected the mutated construct
in TDP-43 depleted cells, the extent of exon skipping did
not change suggesting that the selected tg-gt repeated se-
quence represents the unique TDP-43 binding site in the
pTB/MADD minigene (Figure 4D, right panel).
Mapping the interaction between TDP-43 and STAG2 se-
quences
A similar attempt to recapitulate the splicing of STAG2 us-
ing a single exon (exon 30b with part of its intronic flanking
regions) in the pTBminigene did not result in any changes in
the splicing profile as it produced only skipped transcripts.
This is probably due to the fact that in many minigenes it is
important to maintain as much as possible of the original
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Figure 4. Mapping the functional TDP-43 binding sites in the region surroundingMADD exon 31. (A) Schematic diagram of the minigene system to test
the effect of TDP-43 onMADD exon 31 inclusion (pTB/MADDGTWT). The -globin, fibronectin EDB and humanMADD exon 31 are shown as black,
white and grey boxes, respectively. Diagram on the top shows MADD exon 31 (upper case) together with part of its intronic flanking regions cloned in
the minigene. For the EMSA competition analysis the upstream intron was divided into three fragments (Frag1–3), which are indicated with alternating
bold and plain letters. The underlined tg-gt-repeated sequence in the upstream intron represents the putative TDP-43 binding region. Mutagenesis of the
TDP-43 binding region is shown and indicated as pTB/MADD GT Mut. (B) Band shift competition analysis using recombinant TDP-43 and labelled
(UG)6 RNA. As competitors, cold RNAs of the indicated fragments of exon 31-upstream intron were used. The arrow indicates labelled unbound (UG)6
RNA which increases in accordance with increasing amounts of competitor used. (C) RT-PCR analysis performed on pTB/MADD GT WT-transfected
in HEK293 cells upon treatment with control siRNA Luciferase and TDP-43 siRNA. Schematic representation of the amplicons is shown on the right.
Efficiency of TDP-43 knockdown is shown in the lower panels by western blot. An anti-tubulin antibody was used as protein loading control (bottom of the
panel). ImageJ quantification of exon exclusion percentage and corresponding standard deviations performed on three different experiments are indicated.
(D) RT-PCR performed on HEK293 cells transfected with the minigene carrying the wild-type TDP-43 binding region (pTB/MADD GT wt) and the
mutated one (pTB/MADD GT Mut) upon treatment with control siRNA Luciferase and TDP-43 siRNA. Schematic representation of the amplicons is
shown on the right. Efficiency of TDP-43 knockdown is shown in the lower panels by western blot. An anti-tubulin antibody was used as protein loading
control (bottom of the panel). ImageJ quantification of exon exclusion percentage and corresponding standard deviations performed on three different
experiments are indicated, as well as P-values where *** means P≤ 0.001, ** meansP≤ 0.01 and *meansP≤ 0.05. NS indicates not statistically significant
difference.
genomic milieu in order to successfully reproduce the same
splicing behaviour observed in the endogenous gene (45).
For this reason, a heterologous minigene was constructed,
pcDNA3/STAG2 ex 30–30b-31 that included exon 30, in-
tron 30, exon 30b, most of the downstream intron and exon
31 (see schematic diagram in Figure 5A). Following trans-
fection of thisminigene in TDP-43 depleted cells, it was pos-
sible to confirm that in the absence of this factor the inclu-
sion levels of exon 30b were increased approximately three-
fold (Figure 5A).
Consequently, it was necessary to determine whether
TDP-43 was capable of binding in the vicinity of exon 30b.
However, unlike inMADD, no discernible tg-rich sequences
within the exon or flanking intronic regions were visible,
which made it difficult to identify likely TDP-43 binding
motifs (see scheme in Figure 5B), except for a gt/gc-rich
motif designated as Fragment 4. We then performed a com-
petition binding analysis (Figure 5C) using exon 30b (Frag-
ment 1) and 1041 bp of the downstream intronic region di-
vided into four fragments (Fragments 2–5). In this experi-
ment, in vitro transcribed cold RNAs (the integrity of which
is shown in Supplementary Figure S7B) representing these
different regions were used in a competition assay with WT
GST-TDP-43 bound to a labelled (UG)6 synthetic oligo. As
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Figure 5. Mapping the functional TDP-43 binding sites in the region surrounding STAG2 exon 30b. (A) Schematic diagram of the minigene system to test
the effect of TDP-43 on STAG2 exon 30b inclusion. The STAG2 exon 30 along with its downstream intron, exon 30b along with most of its downstream
intron and exon 31 were cloned in pCDNA 3.1. The lower panel shows an RT-PCR analysis performed on minigene-transfected cells upon treatment with
control Luciferase siRNA (siLuc) and TDP-43 siRNA (siTDP-43). Schematic representation of the amplicons is shown on the right. Efficiency of TDP-43
knockdown is reported in the western blots below. An antibody anti-tubulin was used as protein loading control (bottom panel). ImageJ quantification of
exon exclusion percentage and corresponding standard deviations were performed on three different experiments and are indicated. (B) Sequence of exon
30b (capital letters) together with its downstream intronic region divided into five fragments (Frag.1-Frag.5) shown with alternating bold and plain letters
and used in the EMSA analysis are shown. (C) Band shift competition analysis using recombinant TDP-43 and labelled (UG)6 RNA. As competitor,
cold RNAs of Fragments 1–5 were used. The arrow indicates labelled unbound (UG)6 RNA which increases in accordance with the increasing amount
of fragments number 3 and 5. (D) RT-PCR analysis performed on control Luciferase siRNA and TDP-43 siRNA treated cells following transfection of
STAG2 minigene (named pcDNA3/STAG2ex 30–30b-31) and of the same minigene in which the two TDP-43 binding regions 3 and 5 were depleted
(named pcDNA3/STAG2ex 30–30b-31 3 5). Three replicates for each condition are shown. Schematic representation of the amplicons is shown on
the right. Efficiency of TDP-43 knockdown is shown in the western blot below and an antibody anti-tubulin was used as protein loading control (bottom
panel).
shown in Figure 5C, both fragments 3 and 5 were capable
of successfully competing with the (UG)6 oligo for GST-
TDP-43 binding, confirming that the downstream intronic
regions of exon 30b contain at least two putative binding
sites for this protein. The functional importance of these re-
gions inmediating exon 30b inclusionwas then confirmed at
the minigene level by engineering a mutant that lacks these
two sequences (pcDNA3/STAG2ex 30–30b-31 3-5). As
expected, mRNA analysis after transfection suggests that
TDP-43-binding to Fragments 3 and 5 affects exon 30b
recognition (Figure 5D).
Finally, the same approachwas also attempted for the rel-
evant exons in the FNIP1 and BRD8 genes. However, in
these cases it was impossible to engineer a minigene sys-
tem that could mimic the splicing profile of the endoge-
nous transcript (data not shown). Hence, mapping the exact
TDP-43 binding sites in these genes was not possible and
further work will be required to better characterize these
two splicing events.
Validating the functional effects of STAG2 isoforms in cell
cycle regulation
STAG2 is a subunit of the cohesin complex, which regulates
the separation of sister chromatids during cell division (46).
Therefore, to investigate the potential impact of the TDP-
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43-induced STAG2 exon 30b+ isoform on cells, we decided
to analyse changes on cell cycle distribution following spe-
cific depletion of this STAG2 isoform from cells. To do so,
we engineered two siRNAs that were specifically designed
against the STAG2 exon 30b+ isoform (Figure 6A, upper
diagram, underlined sequences). The efficiency of these siR-
NAs to selectively knockdown this isoform was then tested
together with the silencing of TDP-43 (that greatly increases
its expression). As shown in Figure 6A, lower panels, addi-
tion of the STAG2 ex30b+ siRNAs was capable of specif-
ically downregulating the expression of the STAG2 exon
30b+ isoform even in the presence of siTDP-43, without af-
fecting the expression level of the STAG2 exon 30− isoform.
We therefore proceeded to perform Fluorescence-Activated
Cell Sorting (FACS) analysis on these cell lines to deter-
mine the effects of these changes on cell cycle progression.
As shown in Figure 6B, middle panel, depletion of TDP-
43 with the consequent upregulation of the STAG2 exon
30b+ isoform resulted in an accumulation of cells in the
G2/M phase, as previously reported (16). Strikingly, ad-
ditional treatment of these cells with two specific STAG2
exon 30b+ siRNAs removed the block on G2/M progres-
sion (Figure 6B, lower panel). This experiment was repeated
three times and the results are graphically reported in Fig-
ure 6C.
Altered splicing of the MADD, STAG2, BRD8 and FNIP1
genes using a TDP-43 loss of function model
Considering the involvement of TDP-43 in neuropathology,
it was of interest to investigate whether the same alterations
observed in our stable HEK293 cell lines could similarly be
detected in a TDP-43 loss-of-function system recently de-
veloped in our laboratory (41). Briefly, this system is based
on the tetracycline inducible expression of 12 tandem re-
peats of the Q/N rich region of TDP-43 (residues 342–366)
fused to additional TDP-43 protein sequences. Expression
of this effector causes TDP-43 aggregate formation (Fig-
ure 7A). These aggregates are able to sequester endogenous
TDP-43 depleting it from the nucleus and inducing gen-
eral TDP-43 loss of function effects at the pre-mRNA splic-
ing level (41). Most importantly, this aggregation system
achieves functional effects similar to TDP-43 RNAi deple-
tion at the nuclear level without directly interfering with the
expression of the endogenous gene.
Therefore, following tetracycline induction the effects
of FLAG-TDP-43–12XQ/N expression on the alternative
splicing profiles of SKAR/POLDIP3 (positive control),
MADD,STAG2, BRD8 andFNIP1were determined byRT-
PCR. As shown in Figure 7B (right panels), in the stable cell
line expressing the Flag-TDP43–12XQ/N protein the alter-
ations in these genes closely mimicked the effects of TDP-
43 depletion observed in HEK293 cell lines (Figure 7B, left
panels). In particular, STAG2 exon 30b and BRD8 exon 20
inclusions were both upregulated whilst MADD exon 31
and FNIP1 exon 7 were down regulated. Interestingly, in
the case of the MADD gene, not only skipping of exon 31
but the inclusion of a pseudoexon (47) sequence (marked as
PE, Figure 7B, right panels) upstream of exon 31 was also
observed. Sequencing of this extra band showed that it cor-
responded to a sequence of 115 nt that is flanked by appar-
ently viable donor and acceptor splice sites (Supplementary
Figure S8) but which are never used under normal TDP-43
expression conditions.
Altered splicing of the MADD, STAG2, BRD8 and FNIP1
genes in neuronal cell lines
Finally, to further determine significance of the TDP-43
dependent changes of the previously described genes in a
neuronal context, we analysed neuronal cell lines to deter-
mine if similar alterations could be observed. For this rea-
son, TDP-43 was silenced in both SH-SY-5Y and SK-N-BE
(Supplementary Figure S9A), two neuroblastoma cell lines.
The effects on MADD, STAG2, BRD8 and FNIP1 were
then analysed by RT-PCR. As shown in Supplementary
Figure S9B, in both cell lines the alterations in these genes
closely mimicked the effects of TDP-43 depletion observed
in the stable HEK293 cell lines and in the FLAG-TDP-43–
12XQ/Nexpressing cells. Intriguingly, in these neuronal cell
lines, the inclusion of the pseudoexon in the endogenous
MADD transcript previously identified in the FLAG-TDP-
43–12XQ/N expressing cells was also observed (marked as
PE, Supplementary Figure S9B).
DISCUSSION
In animal models of TDP-43 proteinopathy, a common ob-
servation has been that depletion of TDP-43 is embryonic
lethal at very early stages of development and that its over-
expression above normal levels is highly toxic to cells, es-
pecially neurons (48). Most importantly from the point of
view of the disease, several conditionally TDP-43 knockout
mouse models display ALS phenotypes that are consistent
with a picture in which sequestration of TDP-43 by insolu-
ble aggregates can contribute to this pathology (49–51). In
particular, when partial loss of TDP-43 was achieved using
a synthetic siRNA, several changes in the splicing profiles
of genes already known to be affected by TDP-43 in mouse,
such as Sort1 and Skar/Poldip3 were observed (51). This
is consistent with the central role that this protein plays in
the control of RNA metabolism and protein homeostasis
within cells (7,52) and probably the reason for the tightly
regulated expression levels within cells, mostly through an
auto regulatory feedback loopmechanism that acts through
the 3′UTR of its own mRNA (38,53). In keeping with this
assessment, all recent screening studies performed on this
subject have confirmed that alterations in TDP-43 expres-
sion levels, both in a positive and a negative manner, can
lead to hundreds of changes in the general RNA expres-
sion profile. Most importantly, this occurs for many kinds
of RNAs, whether protein coding mRNAs, microRNAs or
long non-coding RNAs (10,54–57).
Althoughmany of these events/targets have shown a high
degree of variability depending on the tissue/cells analysed
(6), they have all supported the hypothesis that defects at the
RNA processing level, also caused by other factors such as
the recently describedC9orf72 expansion,may considerably
explain TDP-43 role in disease (58,59). What is still lacking,
however, is a clear view of which of these changes are di-
rectly connected with this protein or just reflect secondary
changes of a general deregulation at the RNA expression
level.
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Figure 6. Functional effects of STAG2 exon 30b-containing isoform in TDP-43 depleted cells. (A) The upper panel shows the sequence of STAG2 exon
30b with the siRNA target sequences underlined. The lower panels show the effects of these siRNAs in specifically silencing the expression of this isoform
following treatment with TDP-43 siRNA. (B) Flow cytometry profiles of HeLa cells treated with siRNA Luciferase (upper panel), siRNA TDP-43 (middle
panel) and siRNAs against TDP-43 and STAG2 exon 30b-containing isoform (lower panel). (C) Histogram quantifying the cells distribution in the differ-
ent phases of the cell cycle following differential siRNA treatment of cells illustrated in (B). The quantifications represent the average of three independent
experiments. Corresponding standard deviations were the following: ±1.11, ±0.81, ±0.83 for the siRNA Luciferase treated cells in G1, S, G2/M respec-
tively;±0.83,±0.12,±0.72 for the siTDP-43 treated cells in G1, S, G2/Mrespectively and±0.7,±1.42,±0.93 for the siTDP-43/STAG2 treated cells in G1,
S, G2/M respectively. Significance values were calculated using the Student’s t-test and were the following: for cells in G1 phase P-values were <0.05 for
siRNA Luciferase versus siTDP-43 treated cells, for siRNA Luciferase versus siTDP-43/STAG2 treated cells and for siTDP-43 versus SiTDP-43/STAG2
treated cells; for cells in S-phaseP-values were<0.01 for siRNALuciferase versus SiTDP-43 treated cells, ns for siRNALuciferase versus siTDP-43/STAG2
treated cells and for siTDP-43 versus siTDP-43/STAG2 treated cells; for cells in G2/M phase P-values were <0.05 for siRNA Luciferase versus siTDP-43
treated cells and for for siRNA Luciferase versus siTDP-43/STAG2 treated cells, <0.001 for siTDP-43 versus siTDP-43/STAG2 treated cells.
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Figure 7. Alterations in pre-mRNA splicing levels using a TDP-43 loss of function cellular system. (A) Immunofluorescence of the endogenous TDP-43
present in untreated HEK293 FlpIn-T-Rex and FLAG-TDP-43–12XQ/N cell lines that is predominantly localized in the nucleus (visualized using an anti-
TDP-43 antibody, upper panels). Following tetracycline induction the FLAG-TDP-43–12XQ/N is induced and observed using an anti-FLAG (red, middle
right panels). On the other hand, no FLAG signal is observed when a non-transgenic cell line is treated with Tetracycline (middle left panels). A merge
between anti-FLAG/anti-TDP-43 antibodies is reported in the lower panels showing, in the case of FLAG-TDP-43–12XQ/N cell line, the prominent
aggregate formation in the cytoplasm often accompanied by TDP-43 nuclear clearance. The cell nuclei were stained with the reagent TOPRO-3. (B) shows
the splicing pattern of the endogenous gene SKAR/POLDIP3, STAG2, FNIP1, BRD8 andMADD/IG20 following induction of FLAG-TDP-43–12xQ/N
proteins (right panels, compare −Tet and +Tet lanes). In all cases, the result of knocking down the endogenous TDP-43 is reported (left panels). Exon
inclusion was evaluated by RT-PCR. Schematic representation of the amplicons is shown on the right. Efficiency of TDP-43 knock down is reported in the
western blots below. An antibody anti-tubulin was used as protein loading control (bottom panel). ImageJ quantification of exon inclusion or exclusion
percentage and corresponding standard deviations were performed on three different experiments and are indicated.
Therefore, one of the main issues in today’s research ef-
forts is to determine the major RNA modifying events that
are directly controlled by TDP-43 and whether they could
be potentially affected at the neuronal level in the presence
of aggregation. At present, the principal splicing target in
neuronal and non-neuronal cells that becomes modified ac-
cording to TDP-43 expression levels in a very significant
manner is the SKAR/POLDIP3 gene (36,37). In all the
studies performed so far, in fact, it is shown that TDP-43
knockdown can almost completely shift the expression of
this gene from the predominant  to the  SKAR isoform.
This event results in the more efficient activation of S6K1
(ribosomal protein S6 kinase 1) and increases global protein
translation, suggesting that when TDP-43 is sequestered in
the insoluble aggregates the alteration in the general area of
protein homeostasis may contribute to disease pathogene-
sis. In this work, we now expand this list to four other genes,
MADD, STAG2, BRD8 and FNIP1. Interestingly, an alter-
ation in the splicing of theSTAG2, BRD8 andMADD genes
was also previously reported by Tollervey et al. (60). The
fact that all these genes can be directly affected by TDP-
43 further confirms the role played by TDP-43 in several
pathological directions.
For example, the observation that altered splicing of the
MADD gene can occur following TDP-43 depletion fur-
ther confirms the very important role that TDP-43 protein
plays in the apoptotic pathway. In fact, together with Bcl-2
initially described by Tollervey et al. (60) (and confirmed
in this work), these two genes are very important in en-
suring cellular survival. In particular, the MADD gene is
implicated in cancer cell survival and apoptosis (61) and
can be spliced to yield at least six different splice variants
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of which four are expressed more ubiquitously (MADD,
DENN-SV, IG20pa, IG20-SV2) (62). Interestingly, the ex-
pression of these splice variants has previously been found
to be affected in neuronal cell lines exposed to high concen-
trations of the A-beta peptide (63), suggesting that this is an
important gene for ensuring neuronal survival. In addition,
the finding that TDP-43 can affect the pre-mRNA splicing
of this gene may represent a potentially important link with
the protein produced by theC9orf72 gene, a major player in
the ALS/FTD field, whose structure seems to be related to
that of MADD/DENN Rab-GEFs (64).
At present, we do not know if some of the six possible iso-
forms described for theMADD gene (62) are more affected
than others by the changes in skipping/inclusion of this
exon and further work will be required to better understand
the physiological consequences of this event. Nonetheless,
in our case the changes observed inMADD expression sug-
gest that there is not only a variation in the expression levels
of these isoforms, but also that the TDP-43 induced changes
can lead to a general decrease in its expression.
In the case of STAG2, we identified the TDP-43 intronic
binding regions to be located much further in the down-
stream intron, within a relatively well-conserved region,
suggesting a conserved functional significance. Intriguingly,
it is a pyrimidine-rich sequence, to which TDP-43 has been
reported to bind in some cases. It is interesting to note that
both overexpression and silencing of TDP-43 expression
have been reported to be capable of affecting cell cycle pro-
gression. For example, initial observations by Ayala et al.
showed that TDP-43 silenced U2OS cells displayed alter-
ations in cell cycle progression, with a 60% decrease in cells
at the G0/G1 phase and a corresponding increase in cells
at the S and G2/M phases (16). More recently, Yamashita
et al. have reported that in SH-SY5Y cells overexpressing
a full length wild-type TDP-43 coupled with Green Fluo-
rescent Protein (GFP) there was an accumulation of cells in
the G2/M and subG1 phase, reflecting growth arrest and
apoptosis respectively (65). Finally, Lee et al. have shown
that two- to five-fold overexpression of wild-type TDP-43
in HeLa cells was also capable of inducing partially p53-
dependent G2/M arrest and p53-independent cell death
(66). However, in none of these cases was the direct con-
nection between TDP-43 and cell cycle affecting proteins
was identified. In this regard, the only reported molecular
connection between TDP-43 and cell cycle control was rep-
resented by the possible involvement of gadd7, a long non-
coding RNA in the regulation of the CDK6 expression me-
diated by TDP-43 (56). In this work, we finally provide evi-
dence that at least some of these observed effects of TDP-43
could be mediated by alterations in the pre-mRNA splicing
profile of STAG2, an important component of the cohesin
complex that is required to keep the sister chromatids to-
gether until their separation at anaphase (67). Indeed, we
observed that the altered cell cycle distribution upon silenc-
ing of TDP-43 could be recovered following the additional
silencing of the STAG2 exon 30b+ containing isoform.
From the point of view of the neurodegeneration, cell
cycle dysregulation could have some significance for neu-
ronal pathology as it has been reported that neurons under-
going degeneration re-enter the cell cycle, leading to apop-
tosis rather than cellular division, as recently reviewed by
Campos-Melo et al. (68). In addition, the finding that TDP-
43 can affect STAG2 splicing also offers a new connection
with recent reports that depict its possible role in tumorige-
nesis, since recent cancer genomics analyses have reported
a rather large number of somatic mutations at the level
of the core cohesin factors (SMC1A, SMC3, RAD21 and
STAG1/2) in a particular subset of human tumours includ-
ing Ewing sarcoma, an aggressive bone tumour (69). In this
respect, it is therefore highly interesting to note that a re-
cent GWAS study aimed at identifying risk factors for Ew-
ing sarcoma has found a significant decrease in TDP-43 ex-
pression in tumour material from patients (70) and that its
expression and localization is altered in leukemic cell lines
(71).
In the cases of the FNIP1 andBRD8 genes whose splicing
was considerably affected by TDP-43 there is little litera-
ture to suggest a connection with observed consequences of
TDP-43 depletion from cells. It is nonetheless interesting to
note that FNIP1 together with FNIP2 and folliculin have
been shown to physically interact with AMPK and affect
mTOR activities during cellular differentiation, thus repre-
senting a possible connection with cancer (72).
In conclusion, our results show that in conditions of
TDP-43 loss of function the splicing profiles of several im-
portant genes can significantly be affected in neuronal and
non-neuronal cell lines. The observations that these alter-
ations occur in both neuronal and non-neuronal cell lines,
and that they can also be observed in cellular models mim-
icking TDP-43 aggregation, could represent a starting point
for several strategic aims that include: the development of
novel RNA-based therapeutic strategies aimed at modify-
ing these alterations, for biomarker analysis to monitor dis-
ease onset/progression, or to test any type of therapeutic
efficacy in the human context aimed at restoring TDP-43
functional levels within cells.
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